Abstracts tagged "juvenile idiopathic arthritis (JIA) and registry"

Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting
Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson^6,7 and Kimme L. Hyrich^1,6, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
Abstract Number: 2272 • 2017 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
Daniel J Lovell¹, N Ruperto², N Tzaribachev³, A Zeft⁴, Rolando Cimaz⁵, V Stanevica⁶, Gerd Horneff⁷, John F. Bohnsack⁸, Thomas A. Griffin⁹, R Carrasco¹⁰, Maria Trachana¹¹, Jason A Dare¹², I Foeldvari¹³, Richard K Vehe¹⁴, TA Simon¹⁵, Hermine I. Brunner¹⁶ and Alberto Martini², ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ³University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ⁴Cleveland Clinic, Cleveland, OH, ⁵Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, ⁶Riga Stradins University, Riga, Latvia, ⁷Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ⁸University of Utah School of Medicine, Salt Lake City, UT, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ¹⁰Specially For Children, Austin, TX, ¹¹Hippokration General Hospital, Thessaloniki, Greece, ¹²University of Arkansas for Medical Sciences, Little Rock, AR, ¹³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Bristol-Myers Squibb, Princeton, NJ, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Abatacept is an FDA- and EMA-approved biologic that is widely used in children with juvenile idiopathic arthritis (JIA). The purpose of this long-term ongoing…
Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting
Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Johannes Peter Haas⁴, Toni Hospach⁵, Ralf Trauzeddel⁶, Frank Weller-Heinemann⁷, J B. Kuemmerle-Deschner⁸, Angelika Thon⁹ and BIKER study group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Rheumatology, Scleroderma, Hamburg, Germany, ⁴German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁶HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁷PRINTO, Genoa, Italy, ⁸Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁹Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany
Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…